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Abstract Pituitary adenylate cyclase-activating peptide-
38 (PACAP38) and vasoactive intestinal peptide (VIP)
belong to the same secretin–glucagon superfamily and are
present in nerve fibers in dura and skin. Using a model of
acute cutaneous pain we explored differences in pain per-
ception and vasomotor responses between PACAP38 and
VIP in 16 healthy volunteers in a double-blind, placebo-
controlled, crossover study. All participants received
intradermal injections of 200 pmol PACAP38, 200 pmol
VIP and placebo into the volar forearm. Measurements
included pain intensity on a visual analog scale (VAS),
blood flow by laser Doppler flowmetry, visual flare and
wheal. Pain intensities after PACAP38 and VIP were mild
and limited to a short time of about 100 s after injection.
The area under the VAS-time curve was larger following
PACAP38 (P = 0.004) and VIP (P = 0.01) compared to
placebo. We found no statistical difference in pain per-
ception between PACAP38 and VIP. Skin blood flow
increase, flare and wheal were larger after both PACAP38
(P = 0.011) and VIP (P = 0.001) compared to placebo.
VIP induced a considerably larger increase in skin blood
flow, flare and wheal than PACAP38 (P = 0.002). In
conclusion, we found that peripheral nociceptive cutaneous
responses elicited by PACAP38 and VIP are similar in
healthy volunteers. This suggests that acute pain and
vasomotor responses following intradermal injections of
PACAP38 and VIP are primarily mediated by VPAC
receptors.
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Introduction
Pituitary adenylate cyclase-activating peptide (PACAP)
and vasoactive intestinal peptide (VIP) are members of the
secretin–glucagon superfamily of peptides and involved in
various biological functions, including nociceptive trans-
mission [1]. PACAP and VIP are functionally linked as
both peptides bind to the VPAC1 and VPAC2 receptors
with equal affinity, but PACAP also selectively binds to the
PAC1 receptor [2].
The role of PACAP38, the most predominant PACAP
form in most tissues [3–6], has been explored in an exper-
imental human migraine model [7–9]. It was shown that
intravenous administration of PACAP38 induced acute
headache and delayed migraine-like attacks in migraine
sufferers [9]. In contrast, VIP infusion only induced very
mild headache during infusion and no delayed migraine-
like attacks [8]. These results suggest that PACAP38-
induced migraine could be due to the selective activation of
the PAC1 receptor by PACAP38. The major limitation of
the human migraine model is that peripheral nociceptive
mechanisms in the perivascular space, such as neurogenic
inflammation and mast cell degranulation, cannot be visu-
alized. Furthermore, following intravenous administration it
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is unknown to what extent the experimental drug reaches
sensory nerve endings in perivascular space relevant for
head pain. Given that skin nociceptors show property
characteristics similar to dural nociceptors [10, 11], the
cutaneous model of acute pain offers a method to compare
pain mechanisms between PACAP38 and VIP in an isolated
skin area under controlled conditions. The cutaneous
application of algogenic substances may result in neuro-
genic inflammation shown as increased blood flow and
flare, which are caused by activation of nociceptors and the
subsequent release of substance P (SP) and CGRP [12].
Furthermore, mast cell degranulation can be investigated by
a relatively simple analysis of skin wheal reponse [13],
which reflects a localized vasodilatation and leakage of
plasma proteins from postcapillary venules [14].
The aims of the present study were, in a double-blind
placebo-controlled crossover study, to elucidate the dif-
ferences between PACAP38 and VIP in generating (1)
cutaneous pain; (2) neurogenic inflammation, measured by
increases in skin blood flow and flare; (3) mast cell
degranulation, measured by increase in skin wheal. We
hypothesized that PACAP38 would induce more pain,
neurogenic inflammation and mast cell degranulation
compared to VIP and placebo.
Methods
Sixteen healthy subjects (8 females and 8 males), mean age
27 years (range 19–45), were recruited. The subjects were
in good health condition and did not suffer from any
peripheral vascular disease or neurological or dermatologic
disorder. All subjects were non-smokers and did not take
any daily medication apart from oral contraceptives. All
females were non-pregnant and took oral contraceptives
during the study and for at least 2 days before both study
days, since cutaneous sensory and vasomotor responses
differ throughout the female hormonal cycle [15].
The Committees on Biomedical Research Ethics of
the Capital Region of Denmark approved the study
(HB2008142). All subjects gave informed consent to par-
ticipate in the study that was undertaken in accordance with
the Helsinki Declaration of 1964, as revised in Edinburgh
in 2000.
Design
Using a double-blind, placebo-controlled, crossover design
all participants were, in a balanced order, randomly allo-
cated to receive injections of PACAP38 and placebo or
VIP and placebo (isotonic saline) on two study days sep-
arated by at least 2 days. Thus, each participant received
two injections each day, active substance in one and pla-
cebo in the other arm. One of the investigators (HWS)
performed all the experimental procedures, while each
subject rested in a supine position on a comfortable bed in a
quiet room (temperature of 24–25C). Prior to provocation
participants rested in the supine position for at least 30 min
to reduce influences of experimental conditions on cuta-
neous blood flow [16]. Likewise, intake of coffee, tea,
cocoa, tobacco, methylxanthine-containing foods or bev-
erages was not allowed for the last 4 h before the study
[16].
Spontaneous pain intensity was recorded after the
experimental drug injection. Assessment of skin blood
flow, flare and wheal were recorded 5, 15 and 20 min after
injection of the experimental drug. The validated Danish
version of McGill Pain Questionnaire MPQ [17] was used
to assess the subjective pain quality and pain distribution.
Intradermal injections
All experimental drugs were prepared, blinded and ran-
domised by the Central Pharmacy, Herlev Hospital, Den-
mark. The test substrates were 18.1 lg/ml PACAP38 and
13.3 lg/ml VIP (both Calbiochem, Darmstadt, Germany)
and the pharmacy produced vials with 200 pmol PA-
CAP38 and 200 pmol VIP. The subjects arm was placed
in a comfortable position and 0.05 ml was injected intra-
dermally at an angle of approximately 15 using a 29-
gauge needle (BD Micro-Fine U-100 insulin 0.5 ml
syringes, BD Medical, USA). The injection site was the
flexor side of the forearm 1/3 distal to the cubital fossa, no
more than 1 cm off midline avoiding visible veins. The
injection point was chosen since proximal sites of the
human forearm show the most reproducible and robust
responses to pain activation [18]. In the opposite arm, the
other experimental drug was injected similarly at least 1 h
after the first injection.
Assessment of pain intensity, distribution and quality
Experimental drug-induced pain intensity was recorded
continuously every 2 s on a 10 cm electronic visual analog
scale (VAS), with anchor points 0 = no pain and 10 = the
worst imaginable pain. Data were collected in a computer
for later analysis. Subjects did not see the numeric corre-
lates to their pain perceptions at any point during the study.
Experimental drug-induced pain was determined and
expressed as area under the VAS–time curve (VASAUC,
cm 9 min), peak pain intensity and pain time (total time
period of reported pain). When testing and recording of the
investigated arm were completed, the subject chose the
appropriate descriptor words of the MPQ and was asked to
draw the perceived pain distribution on an arm chart. The
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pain distribution area was later quantified by cutting and
weighing the pain drawing using an analysis weight
(readability 0.1 mg, Mettler Toledo AJ 150-L, Greifensee,
Switzerland).
Assessment of skin blood flow
The forearm skin blood flow was measured by laser
Doppler flowmetry (LDI, Moor Instruments, Devon, UK).
An area of 4 9 4 cm was scanned with the injection in the
center of the area at a distance of 30 cm from the skin. The
image resolution was obtained at 114 9 114 pixels with a
scan speed of 4 ms/pixel. Bandwidth was set at 250 Hz to
15 kHz. Each single scan lasted 69 s. Relative blood flow
changes (expressed in %) were calculated by subtracting
the baseline blood flow from blood flow at 5, 15 and
20 min after injection of the experimental drug.
Assessment of flare
Flare (erythema around the injection site) was identified
visually by HWS and mapped 5, 15 and 20 min after the
injection on an acetate sheet. The flare areas were subse-
quently quantified by cutting and weighing the maps on a
laboratory weight (readability 0.1 mg, Mettler Toledo AJ
150-L, Greifensee, Switzerland).
Assessment of wheal
The wheal (the area of edema caused by plasma extrava-
sation) was inspected visually and by light palpation by
HWS 5, 15 and 20 min after the injection. Afterward the
wheal was outlined with a marker pen on transparent
removable tape above the wheal and the tape was pasted on
millimeter paper and later calculated to total wheal area (in
mm2).
Statistical analysis
The pain scores are expressed as median values with
quartiles. Other variables are expressed as mean values
with standard deviation (±SD). PACAP38 was compared
to placebo on the opposite arm on the injection day and the
same was done for VIP, since it has been shown that arm-
to-arm comparison is more reproducible than period-to-
period comparison [18].
The primary endpoint was difference in the area under
VAS-time curve (VASAUC) between PACAP38 versus
placebo, VIP versus placebo and PACAP38 versus VIP.
The secondary endpoints were difference in maximum skin
blood flow change, flare, wheal and pain distribution
between PACAP38 versus placebo, VIP versus placebo and
PACAP38 versus VIP. Peak pain intensity and pain time
were also obtained but not analyzed statistically. Given that
the data were not normally distributed, we performed
Friedman’s two-way analysis of variance for the four
groups: PACAP38, VIP, placebo on VIP day and placebo
on PACAP38 day. If the overall P value was less than 0.05,
we applied a post hoc Wilcoxon signed rank test to test the
differences between relevant groups for which the signifi-
cance level P \ 0.05 was also chosen. SPSS (version 16.0)
was used for statistical analysis.
Results
All 16 subjects completed both study days and no data
were missing. There were no differences between the two
placebo injections for any test variable.
Pain intensity
Pain after PACAP38 and VIP was mild and limited to a
short time of about 100 s after the injection (Fig. 1 and
Table 1).
The Friedman’s two-way analysis of variance revealed
that the VASAUC depended on the injected substance
(P \ 0.001). Post hoc analysis showed that the VASAUC
was larger following PACAP38 (P = 0.004) and VIP
(P = 0.01) than after placebo. No statistical difference was
found for PACAP38 compared to VIP (P = 0.255). The
pain distribution area depended on the injected substance
(P \ 0.001). Post hoc analysis revealed that pain distri-
bution area was larger after PACAP38 (P = 0.001) and
VIP (P = 0.023) than after placebo. No statistical differ-
ence was found between PACAP38 and VIP (P = 0.215).




















Fig. 1 Median pain scores following injection of 200 pmol VIP and
200 pmol PACAP38. Median pain score did not exceed 0 on any
placebo day. Area under VAS-time curve was larger following VIP
(P = 0.01) and PACAP38 (P = 0.004) compared to placebo
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The most frequent descriptor words in the MPQ after
injections are listed in Table 2.
Skin Blood flow change
The increase in skin blood flow depended on the injected
substance (P \ 0.001) (Figs. 2 and 3). Post hoc analysis
revealed a maximal increase in skin blood flow after PA-
CAP38 and VIP 5 min after injection, which was larger
than compared to placebo (P \ 0.001). VIP induced a
larger maximal increase in skin blood flow than PACAP38
(P = 0.002).
Visible flare
The flare area depended on the injected substance
(P \ 0.001) (Fig. 3). Post hoc analysis revealed a maximal
flare area 5 min after PACAP38, which was larger com-
pared to placebo (P \ 0.001). The maximal flare area
following VIP also occurred 5 min after injection and was
larger compared to placebo (P \ 0.001). VIP induced a
larger maximal flare area than PACAP38 (P = 0.001) at
5 min after injection.
Wheal
The wheal area depended on the injected substance
(P \ 0.001) (Fig. 3). Post hoc analysis revealed a maximal
wheal area 20 min after PACAP38, which was larger
compared to placebo (P = 0.011). The maximal wheal
area after VIP also occurred 20 min after injection and was
larger compared to placebo (P = 0.001). The VIP-induced
wheal area was larger than PACAP38-induced wheal
(P = 0.001) at 20 min after injection.
Study safety
The volunteers tolerated the intradermal experimental drug
injections to the forearm well and no adverse events or
complaints were reported.
Discussion
PACAP38 and VIP both evoked cutaneous pain, increased
blood flow and flare (neurogenic inflammation) as well as
wheal (mast cell degranulation). Surprisingly, PACAP38
induced mild short-lasting pain that was not different from
VIP-induced pain. Furthermore, VIP induced more blood
flow, flare and wheal than PACAP38. These data indicate
that the PAC1 receptor activation is not involved in acute
pain, neurogenic inflammation and mast cell degranulation.
Localization of receptors and nociceptors
Nociceptors are present in the human epidermis and dermis,
along the wall of blood vessels, around sweat glands and hair
follicles [19, 20]. Immunohistochemical studies have shown
that PACAP38- and VIP-immunoreactive nerve fibers are
present in human skin close to mast cells, sweat glands and
hair follicles [20–24]. The peptides have equal affinity for
the VPAC1 and VPAC2 receptors, but only PACAP acti-
vates the PAC1 receptor. VPAC1 and VPAC2 receptors
have been visualized on dermal vessel walls [25, 26] and the
PAC1 receptor has been identified in skin tissue [23]. So far,
however, no studies have attempted to identify VIP/PACAP
receptors on human sensory dermal nociceptors. Human
skin mast cells express higher levels of VPAC2 mRNA
compared to VPAC1 mRNA [22]. Collectively, these data
suggest that PACAP38 and VIP might have modulatory
effects on nociceptive processing in the human skin.
PACAP38 and VIP induced cutaneous pain
To our knowledge, this study is the first to explore differ-
ences in pain responses between PACAP38 and VIP. We
found that intradermal injection of PACAP38 and VIP
induced pain to an equal degree. One study reported that
intradermal injection of 150 pmol VIP evoked pain [27],
but pain intensity was not precisely described. In the
present study the pain area was larger after PACAP38
and VIP than placebo. This may suggest activation of
nociceptors, with larger receptive fields than nociceptors
Table 1 Median values with quartiles, except pain distribution as
mean (±SD)
VIP PACAP38 Placebo
VASAUC (cm 9 s) 1.2 (0.6–1.7)* 1.0 (0.4–1.6)* 0.2 (0–0.4)
Pain distribution
area (cm2)
5.3 ± 8.0* 2.9 ± 5.3* 1.6 ± 3.5
Peak pain (VAS) 1.3 (0.9–2.8) 1.7 (1.0–2.2) 0.5 (0–1.2)
Pain time (s) 96 (83–136) 63 (49–120) 26 (2–59)
VASAUC area under VAS-time curve, * P \ 0.05 for active drug
versus placebo
Placebo values are shown as a mean of placebo on VIP and PACAP38
day
Peak pain and time were not analyzed statistically
Table 2 Words chosen by 30% and more of subjects in the McGill
Pain Questionnaire (MPQ)
VIP % PACAP38 % Placebo %
Boring 44 Boring 56 Boring 41
Annoying 31 Sharp 31 Tender 41
Taut 38
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activated by placebo. Surprisingly, our study revealed no
difference in pain perception between PACAP38 and VIP.
Given that PACAP38 induces more headache than VIP and
response properties of cutaneous and dural nociceptors
seem similar [10, 11] we expected more pain after PA-
CAP38 than after VIP. This would have indicated that the
PAC1 receptor plays a key role in nociceptive processing
of sensory afferents and explain the difference in head pain
responses. One limitation of the present study was that we
did not examine the dose response effects of PACAP38 and
VIP. However, neuropeptides implicated in migraine
pathogenesis have usually been investigated in cutaneous
pain models in the range of 50–500 pmol [28–30] and were
shown to be suitable dosages when investigating pain,
wheal and flare.
VIP- and PACAP38-induced blood flow,
flare and wheal
Intradermal injection of VIP induces histamine release in
human skin in vivo measured with microdialysis technique
[31] and produces both a wheal and flare reaction within a
few minutes of similar degree as in our study [27, 32, 33]. In
contrast, intradermal capsaicin injection induces flare, but
not wheal [34]. Topical capsaicin pre-treatment inhibits
neurogenic inflammation (shown as flare) by depletion of
nociceptors [13]. This robustly inhibits VIP induced skin
flare, but does not affect the wheal reaction, which therefore
most likely is caused by mast cell degranulation [13]. Thus,
VIP is likely to induce neurogenic inflammation and mast
cell degranulation via two different mechanisms. In the
present study we found that VIP increased skin blood flow
and flare more than PACAP38, which is in agreement with a
previous study [35]. Intradermal histamine injection indu-
ces increased skin wheal [36]. PACAP38 causes histamine
release in human skin, but much less than compared to VIP
and PACAP27 [24]. Thus, these data explain the larger
wheal area following VIP injection compared to PACAP38.
At present we cannot exclude that VIP and PACAP could
induce receptor-independent direct activation of mast cells,
which have been suggested in an animal model [37], and
might explain the differences in wheal responses.
Present study in relation to VIP and PACAP38 models
of migraine
We acknowledge possible physiological differences in
tissue responses and therefore the extrapolation of data
Fig. 2 Example of flow
responses measured with laser
Doppler flowmetry to placebo,
200 pmol PACAP38 and
200 pmol VIP in one subject
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from cutaneous model into intravenous models of migraine
is critical. Activation and sensitization of dural nociceptors
may play a key role in generation of head and migraine
pain [38, 39]. As dural nociceptors have properties similar
to the skin nociceptors [10, 11] the human skin seems to be
a suitable compartment for human in vivo investigations of
neuropeptides involved in neurovascular headaches. Fur-
thermore, the present human model of acute cutaneous pain
is a well validated model [18, 40], suitable to test and
compare pain mechanisms in an isolated area under con-
trolled conditions.
We have previously proposed that PAC1 receptor acti-
vation is a likely mechanism of PACAP38-induced delayed
migraine-like attacks [9]. In the present study the induction
of cutaneous pain, apparent neurogenic inflammation and
mast cell degranulation all seem to be driven by VPAC
receptor activation. Such mechanisms may contribute to
pain during spontaneous and experimental migraine attacks
[41–43]. This raises the question as to why VIP infusion does
not induce delayed headaches and migraine-like attacks?
In the present study 200 pmol of PACAP38 or VIP
injected at a single point into the dermis induced short-
lasting pain. This was caused by a high local concentration
of peptides in the dermis, which cannot be expected to be
reached when 200 pmol/kg PACAP38 or VIP are intrave-
nously infused. In human experimental migraine studies, it
is very rare that an experimental drug induces pain else-
where than the head [8, 44–48]. Thus, cephalic vessels are
either surrounded by nociceptors with different and more
sensitive properties than in other organs, or headache is
caused by other mechanisms. It would be interesting to
examine a group of migraine patients, to explore if cuta-
neous pain responses differ between migraineurs and
healthy controls.
Various signaling molecules, such as CGRP and pros-
taglandin I2, do not induce neurogenic inflammation in
human skin models [30, 32], but are known to induce
migraine-like attacks [45, 49]. Mast cell degranulation may
also play a role in migraine pathogenesis [50, 51]. Yet, VIP
only showed a modest (10%) effect on histamine release in
rat dura mater [52]. More neurogenic inflammation and
mast cell degranulation after VIP than after PACAP38
question these phenomena as causative in PACAP38-
induced delayed migraine-like attacks. Thus, PACAP38
might induce a yet unknown cascade of events taking hours
to result in migraine-like attacks, which are probably dri-
ven by PAC1 receptor activation.
Conclusion
Intradermal injections of PACAP38 and VIP in the forearm
of human volunteers evoked equal pain responses. Inter-
estingly, VIP induced larger blood flow and flare as well as
wheal responses as compared to PACAP38. This suggests
VPAC receptor activation as causative for acute pain,
neurogenic inflammation and mast cell degranulation in a


























































Fig. 3 a Increase from baseline (in %) in cutaneous blood flow
measured with laser Doppler flowmetry. b Flare area (in cm2) after
injection of experimental drug. c Wheal area (in mm2) after injection
of experimental drug. * P \ 0.05 for active drugs versus placebo; #
P \ 0.05 for VIP versus PACAP38. Error lines are ?1 SD
314 J Headache Pain (2010) 11:309–316
123
Acknowledgments The authors wish to thank lab technicians
Winnie Grønning Nielsen and Lene Elkjær for their excellent and
dedicated assistance with data processing. The study was supported
by the Lundbeck Foundation via the Lundbeck Foundation Center for
Neurovascular Signaling (LUCENS).
Conflict of interest None.
References
1. Dickinson T, Fleetwood-Walker SM (1999) VIP and PACAP:
very important in pain? Trends Pharmacol Sci 20:324–329
2. Dickson L, Aramori I, Sharkey J, Finlayson K (2006) VIP and
PACAP receptor pharmacology: a comparison of intracellular
signaling pathways. Ann N Y Acad Sci 1070:239–242
3. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH,
Kitada C (1991) Tissue distribution of PACAP as determined by
RIA: highly abundant in the rat brain and testes. Endocrinology
129:2787–2789
4. Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM,
Bloom SR (1993) Distribution, molecular characterization of
pituitary adenylate cyclase-activating polypeptide and its pre-
cursor encoding messenger RNA in human and rat tissues.
J Endocrinol 136:159–166
5. Hannibal J, Mikkelsen JD, Clausen H, Holst JJ, Wulff BS,
Fahrenkrug J (1995) Gene expression of pituitary adenylate
cyclase activating polypeptide (PACAP) in the rat hypothalamus.
Regul Pept 55:133–148
6. Mikkelsen JD, Hannibal J, Fahrenkrug J, Larsen PJ, Olcese J,
McArdle C (1995) Pituitary adenylate cyclase activating peptide-
38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP)
in the rat median eminence and pituitary. J Neuroendocrinol
7:47–55
7. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahr-
enkrug J et al (2006) Vasoactive intestinal polypeptide evokes
only a minimal headache in healthy volunteers. Cephalalgia
26:992–1003
8. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J,
Ashina M (2008) Vasoactive intestinal peptide causes marked
cephalic vasodilation, but does not induce migraine. Cephalalgia
28:226–236
9. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M
(2009) PACAP38 induces migraine-like attacks in patients with
migraine without aura. Brain 132:16–25
10. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff
M (2006) Neuronal control of skin function: the skin as a neu-
roimmunoendocrine organ. Physiol Rev 86:1309–1379
11. Strassman AM, Levy D (2006) Response properties of dural
nociceptors in relation to headache. J Neurophysiol 95:1298–
1306
12. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjork HE,
Handwerker HO (2000) Which nerve fibers mediate the axon
reflex flare in human skin? Neuroreport 11:645–648
13. Anand P, Bloom SR, McGregor GP (1983) Topical capsaicin
pretreatment inhibits axon reflex vasodilatation caused by
somatostatin and vasoactive intestinal polypeptide in human skin.
Br J Pharmacol 78:665–669
14. Raud J, Dahlen SE, Smedegard G, Hedqvist P (1989) An intra-
vital microscopic model for mast cell-dependent inflammation in
the hamster cheek pouch. Acta Physiol Scand 135:95–105
15. Gazerani P, Andersen OK, Arendt-Nielsen L (2005) A human
experimental capsaicin model for trigeminal sensitization.
Gender-specific differences. Pain 118:155–163
16. Fullerton A, Fischer T, Lahti A, Wilhelm KP, Takiwaki H, Serup
J (1996) Guidelines for measurement of skin colour and ery-
thema. A report from the Standardization Group of the European
Society of Contact Dermatitis. Contact Dermatitis 35:1–10
17. Drewes AM, Helweg-Larsen S, Petersen P, Brennum J,
Andreasen A, Poulsen LH, Jensen TS (1993) McGill Pain
Questionnaire translated into Danish: experimental and clinical
findings. Clin J Pain 9:80–87
18. Van der Schueren BJ, de Hoon JN, Vanmolkot FH, Van Hecken
A, Depre M, Kane SA et al (2007) Reproducibility of the cap-
saicin-induced dermal blood flow response as assessed by laser
Doppler perfusion imaging. Br J Clin Pharmacol 64:580–590
19. Dalsgaard CJ, Rydh M, Haegerstrand A (1989) Cutaneous
innervation in man visualized with protein gene product 9.5 (PGP
9.5) antibodies. Histochemistry 92:385–390
20. Schulze E, Witt M, Fink T, Hofer A, Funk RH (1997) Immu-
nohistochemical detection of human skin nerve fibers. Acta
Histochem 99:301–309
21. Savage MV, Brengelmann GL, Buchan AM, Freund PR (1990)
Cystic fibrosis, vasoactive intestinal polypeptide, and active
cutaneous vasodilation. J Appl Physiol 69:2149–2154
22. Groneberg DA, Welker P, Fischer TC, Dinh QT, Grutzkau A,
Peiser C et al (2003) Down-regulation of vasoactive intestinal
polypeptide receptor expression in atopic dermatitis. J Allergy
Clin Immunol 111:1099–1105
23. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A,
Jarry H, Schmidt WE (1999) Identification of pituitary adenylate
cyclase activating polypeptide (PACAP) and PACAP type 1
receptor in human skin: expression of PACAP-38 is increased in
patients with psoriasis. Regul Pept 80:49–55
24. Odum L, Petersen LJ, Skov PS, Ebskov LB (1998) Pituitary
adenylate cyclase activating polypeptide (PACAP) is localized in
human dermal neurons and causes histamine release from skin
mast cells. Inflamm Res 47:488–492
25. Lundeberg L, Nordlind K (1999) Vasoactive intestinal polypep-
tide in allergic contact dermatitis: an immunohistochemical and
radioimmunoassay study. Arch Dermatol Res 291:201–206
26. Fischer TC, Dinh QT, Peiser C, Loser C, Fischer A, Groneberg
DA (2002) Simultaneous detection of receptor mRNA and ligand
protein in human skin tissues. J Cutan Pathol 29:65–71
27. Rukwied R, Heyer G (1999) Administration of acetylcholine and
vasoactive intestinal polypeptide to atopic eczema patients. Exp
Dermatol 8:39–45
28. Jensen K, Tuxen C, Pedersen-Bjergaard U, Jansen I, Edvinsson L,
Olesen J (1990) Pain, wheal and flare in human forearm skin
induced by bradykinin and 5-hydroxytryptamine. Peptides
11:1133–1138
29. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L,
Jansen I, Olesen J (1989) Algesia and local responses induced by
neurokinin A and substance P in human skin and temporal
muscle. Peptides 10:1147–1152
30. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L,
Jansen I, Olesen J (1991) Calcitonin gene-related peptide, neu-
rokinin A and substance P: effects on nociception and neurogenic
inflammation in human skin and temporal muscle. Peptides
12:333–337
31. Huttunen M, Harvima IT, Ackermann L, Harvima RJ, Naukkarinen
A, Horsmanheimo M (1996) Neuropeptide- and capsaicin-induced
histamine release in skin monitored with the microdialysis tech-
nique. Acta Derm Venereol 76:205–209
32. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ
(1986) Potent vasodilator activity of calcitonin gene-related
peptide in human skin. J Invest Dermatol 87:533–536
33. Fjellner B, Hagermark O (1981) Studies on pruritogenic and
histamine-releasing effects of some putative peptide neurotrans-
mitters. Acta Derm Venereol 61:245–250
J Headache Pain (2010) 11:309–316 315
123
34. Sikand P, Shimada SG, Green BG, LaMotte RH (2009) Similar
itch and nociceptive sensations evoked by punctate cutaneous
application of capsaicin, histamine and cowhage. Pain 144:66–75
35. Warren JB, Cockcroft JR, Larkin SW, Kajekar R, Macrae A,
Ghatei MA, Bloom SR (1992) Pituitary adenylate cyclase acti-
vating polypeptide is a potent vasodilator in humans. J Cardio-
vasc Pharmacol 20:83–87
36. Hovell CJ, Beasley CR, Mani R, Holgate ST (1987) Laser
Doppler flowmetry for determining changes in cutaneous blood
flow following intradermal injection of histamine. Clin Allergy
17:469–479
37. Seebeck J, Kruse ML, Schmidt-Choudry A, Schmidt WE (1998)
Pituitary adenylate cyclase activating polypeptide induces
degranulation of rat peritoneal mast cells via high-affinity PA-
CAP receptor-independent activation of G proteins. Ann N Y
Acad Sci 865:141–146
38. Burstein R, Yamamura H, Malick A, Strassman AM (1998)
Chemical stimulation of the intracranial dura induces enhanced
responses to facial stimulation in brain stem trigeminal neurons.
J Neurophysiol 79:964–982
39. Strassman AM, Raymond SA, Burstein R (1996) Sensitization of
meningeal sensory neurons and the origin of headaches. Nature
384:560–564
40. Gazerani P, Andersen OK, Arendt-Nielsen L (2007) Site-specific,
dose-dependent, and sex-related responses to the experimental pain
model induced by intradermal injection of capsaicin to the fore-
heads and forearms of healthy humans. J Orofac Pain 21:289–302
41. Moskowitz MA (1993) Neurogenic inflammation in the patho-
physiology and treatment of migraine. Neurology 43:S16–S20
42. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM
(2007) Mast cell degranulation activates a pain pathway under-
lying migraine headache. Pain 130:166–176
43. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH
(2000) An association between migraine and cutaneous allodynia.
Ann Neurol 47:614–624
44. Wienecke T, Olesen J, Oturai PS, Ashina M (2009) Prostaglandin
E2(PGE2) induces headache in healthy subjects. Cephalalgia
29:509–519
45. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B,
Olesen J (2002) CGRP may play a causative role in migraine.
Cephalalgia 22:54–61
46. Lassen LH, Thomsen LL, Olesen J (1995) Histamine induces
migraine via the H1-receptor. Support for the NO hypothesis of
migraine. Neuroreport 6:1475–1479
47. Wienecke T, Olesen J, Oturai PS, Ashina M (2008) Prostacyclin
(epoprostenol) induces headache in healthy subjects. Pain
139:106–116
48. Schytz HW, Wienecke T, Olesen J, Ashina M (2009) Carbachol
induces headache, but not migraine-like attacks, in migraine
without aura patients. Cephalalgia (In press)
49. Wienecke T, Olesen J, Ashina M (2009) Prostaglandin I2 (Epo-
prostenol) triggers migraine-like attacks in migraineurs. Cepha-
lalgia (In Press)
50. Levy D (2009) Migraine pain, meningeal inflammation, and mast
cells. Curr Pain Headache Rep 13:237–240
51. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstan-
tinidou A (2005) The role of mast cells in migraine pathophysi-
ology. Brain Res Brain Res Rev 49:65–76
52. Ottosson A, Edvinsson L (1997) Release of histamine from dural
mast cells by substance P and calcitonin gene-related peptide.
Cephalalgia 17:166–174
316 J Headache Pain (2010) 11:309–316
123
